Start the conversation with LUCEMYRA®

LUCEMYRA is the only FDA-approved, non-controlled treatment for the relief of multiple symptoms of opioid withdrawal in adults1 

Photos within this website are actor portrayals.

LUCEMYRA is an in-patient or out-patient treatment for patients experiencing:

Opioid Detox

Help patients mitigate withdrawal symptoms when seeking an opioid-free in-patient or out-patient treatment program.

Initiation of Buprenorphine

Prior to the induction of sublingual buprenorphine, ease patients through the 72-hour period of abstinence often needed to avoid precipitating withdrawal.

Transition from Methadone
to Buprenorphine

Help alleviate withdrawal symptoms in patients discontinuing methadone prior to a buprenorphine regimen.

Transition to Extended-Release

Help mitigate withdrawal symptoms during the 7- to 14-day abstinence period for patients transitioning to extended-release naltrexone injections.

Unplanned Disruptions in Treatment

Help mitigate withdrawal symptoms in patients with unplanned disruption of opioid treatment when opioid-agonists are unavailable or inappropriate for the situation.

After-Treatment Care

Help patients who have completed a successful MAT regimen with buprenorphine or methadone and are set to experience withdrawal symptoms from final step-down off treatment.

Discover how LUCEMYRA helped patients relieve the symptoms of opioid withdrawal

2020 ASAM National Practice Guideline: Recommendations for Treating Opioid Withdrawal2

The American Society of Addiction Medicine (ASAM) recognizes two main strategies for managing opioid withdrawal: gradually tapering the dose of the current opioid(s), or using a non-opioid medication, like LUCEMYRA (lofexidine).

Regarding the use of alpha-2 adrenergic agonists, the Guideline states:

“Lofexidine should therefore be the preferred choice for withdrawal management in an outpatient setting, where monitoring of blood pressure and management of hypotension is more difficult.”

-American Society of Addiction Medicine, 2020

Learn more about the 2020 ASAM Guidelines

1. LUCEMYRA® (lofexidine) [Prescribing Information]. USWM, LLC; 2020.
2. American Society of Addiction Medicine (ASAM). National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update. 2020. Accessed July 13, 2020.